Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-15

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

NCT07223502

Hypertension (HTN)

RECRUITING PHASE3

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

NCT06205407

Healthy Participants

COMPLETED PHASE1

Bioequivalence Study of Spironolactone Tablets in Healthy Subjects

NCT06579053

Bioequivalence Study

COMPLETED PHASE1

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

NCT06995144

Heart Failure Edema Pulmonary Congestion +1 more

RECRUITING PHASE4

The Effect of Amiloride and Spironolactone in Healthy Persons

NCT00857909

High Blood Pressure

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To study intrasubject variability and steady-state pharmacokinetics of the multiple-doses of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) (12 mg ER Torsemide and 15 mg Spironolactone) tablet and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) tablets given together in healthy adult subjects. In addition, torsemide, sodium, potassium, and creatinine will be measured in the urine samples.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bioavailability Heathy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Open label, randomized, two-period, two-sequence, balanced, multiple-dose crossover intrasubject variability and steady-state BA/BE study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

The study is of randomized open label design; as it is not essential to design the study as double-blind for assessing bioavailability of formulations. The analyst will not have access to the randomization scheme.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1 FDC

Fixed Dose Combination (FDC) 12 mg ER Torsemide and 15 mg Spironolactone tablet

Group Type ACTIVE_COMPARATOR

Torsemide and Spironolactone tablet

Intervention Type DRUG

Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet

Torsemide Tablets and Spironolactone Tablets

Intervention Type DRUG

10 mg Torsemide tablet and 25 mg Spironolactone tablet given together

Arm 2 (Torsemide tablets and Spironolactone tablets)

10 mg Torsemide and 25 mg Spironolactone tablets given together

Group Type ACTIVE_COMPARATOR

Torsemide and Spironolactone tablet

Intervention Type DRUG

Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet

Torsemide Tablets and Spironolactone Tablets

Intervention Type DRUG

10 mg Torsemide tablet and 25 mg Spironolactone tablet given together

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Torsemide and Spironolactone tablet

Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet

Intervention Type DRUG

Torsemide Tablets and Spironolactone Tablets

10 mg Torsemide tablet and 25 mg Spironolactone tablet given together

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects must fulfill all of the following criteria to be considered for inclusion into this study:

1. Healthy human adult subjects within the age range of 18 to 45 years \[both inclusive\].
2. Weight not less than 50 kg for male and 45 kg for female and BMI 18.50 to 29.99 kg/m2 \[both inclusive\].
3. Willingness to provide written informed consent to participate in the study.
4. Subjects should be non-smoker \[defined as someone who has stopped smoking for a year before the date of screening\] and should not be consuming tobacco containing products.
5. Free of significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12-lead ECG, Chest X-ray \[PA view\].
6. Absence of disease markers of HIV 1 and 2, Hepatitis B and C and Syphilis.
7. Subject should be literate.
8. Male subjects must be using two acceptable methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the study, and upto the study completion visit. Subjects must refrain from fathering a child in the next two weeks following the last study drug administration or have undergone vasectomy (vasectomy must have been done more than 6 months prior to first dosing). Contraceptive usage requirement will be conveyed during the inform consent process. Subjects will be advised to follow effective method of contraception until 2 weeks after the last dose is given.
9. Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study and for two weeks following the last study drug administration. Contraceptive usage requirement will be conveyed during the inform consent process (or) Postmenopausal women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).

Exclusion Criteria

Any of the following conditions are cause for exclusion from the study:

1. History or presence of significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, psychiatric disease/disorder.
2. History or presence of significance:

Asthma, urticaria, or other allergic-type reactions after taking Torsemide, Spironolactone or any other drug.

Ulceration or history of gastric and/or duodenal ulcer. Stomach or intestinal bleeding. Jaundice in the past 6 months. Internal bleeding.
3. Hypersensitivity or allergy to Torsemide, Spironolactone or any of the excipients.
4. History of alcohol or drug abuse in the past one year.
5. Family history of bleeding disorders.
6. History of difficulty in passing urine or emptying the bladder or of incontinence.
7. Have donated 500 mL or more blood within 90 days before receiving the first dose of the study drug.
8. Subjects who have participated in another clinical study in the past 3 months prior to commencement of this study.
9. Any difficulty in the accessibility of forearm veins for cannulation or blood sampling and or difficulty with donating blood.
10. Refuse to abstain from food for at least 10 h prior to dosing and for at least 4 h after dosing in each period.
11. Refuse to abstain from fluid for at least 1 h before and 1 h after dosing in each period (except 240 ± 2 mL water given for dosing).
12. Found positive during breath alcohol test done during period one check-in and inability to abstain from alcohol till the end of the study.
13. Found positive during urine drug screening done prior to period one check-in.
14. Found positive screening results for Hepatitis B, Hepatitis C, HIV, or Syphilis.
15. History of difficulty in swallowing tablets.
16. Received any medication \[including over-the-counter products\], herbal products for 14 days preceding the study.
17. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
18. History of dehydration from diarrhea, vomiting, or any other reason within 24 hours prior to check-in of period one.
19. Consumption of xanthine-containing food and beverages (chocolates, tea, coffee, or cola drinks) for at least 48 hours prior to check-in of period one.
20. Consumption of grapefruit or its products within the 48 hours prior to check-in of period one.
21. Female subjects are found to be positive during pregnancy tests done prior to period one check-in.
22. Lactating females.
23. Investigator/Physician feels that it is not in the subject's and/or study's best interest to enroll the subject.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes